Global Obesity Drug Market Hits 150 Billion Dollars as Novo Nordisk Eli Lilly Battle for Dominance

GLP-1 Obesity Drugs Cross 150 Billion Dollar Market Threshold as Demand Outpaces Supply

The numbers are staggering. The global market for GLP-1 receptor agonist medications — the class of drugs that includes Ozempic, Wegovy, Mounjaro, and Zepbound — crossed an annualized revenue threshold of $150 billion in February 2026, according to combined earnings disclosures from Novo Nordisk and Eli Lilly released Wednesday. That figure, which did not exist as a market category five years ago, now exceeds the global revenue of the entire oncology drug sector.

Novo Nordisk reported fourth-quarter 2025 revenue of $14.7 billion, driven overwhelmingly by Wegovy and semaglutide products, a 38 percent increase year over year. Eli Lilly reported $11.8 billion in fourth-quarter revenue with Zepbound and Mounjaro accounting for $6.3 billion of that total — a figure that exceeded Wall Street consensus estimates by nearly $800 million.

Supply Constraints, Market Expansion, and New Patient Populations

Despite surging revenue, both companies continue to struggle with manufacturing capacity. Novo Nordisk has invested more than $6 billion in production facility expansion since 2023, but patient waiting lists for Wegovy in the United States, United Kingdom, and Germany remain months long. Eli Lilly's Zepbound supply has improved markedly after a dedicated U.S. manufacturing site came online in December 2025, but global supply remains constrained.

The patient population for these drugs continues to expand beyond the original obesity indication. Semaglutide has received regulatory approvals for cardiovascular disease prevention, chronic kidney disease management, and sleep apnea treatment in the past 18 months. Tirzepatide's label is expanding similarly. Each new approved indication opens an entirely new prescribing pipeline.

According to Dr. David Mateson, chief medical officer at the Obesity Medicine Association, we are at the beginning of a long-term shift in how medicine manages a condition that affects 40 percent of American adults. These drugs are not a trend. They are becoming as foundational to chronic disease management as statins were in the 1990s.

Competition, Generics, and the Long-Term Market Outlook

Novo Nordisk and Eli Lilly together control approximately 87 percent of the current GLP-1 market, but competition is intensifying. Amgen's oral GLP-1 candidate, MariTide, is in Phase 3 trials and could reach market by late 2027. Pfizer has two oral candidates in clinical development. Roche and Viking Therapeutics are advancing their own molecules. The prospect of an oral formulation — avoiding weekly injections — is widely seen as the next major commercial breakthrough in the category.

Compounding pharmacies in the U.S. legally produced semaglutide at reduced cost during the shortage period, but the FDA ended that authorization in late 2025 as supply normalized. Litigation between compounders and the major manufacturers continues in several federal courts.

Generic competition is still years away — patent protection on the key molecules runs through the early 2030s — but the competitive pressure from new entrants, oral formulations, and biosimilars will fundamentally reshape the market's economics long before then. For now, Novo Nordisk and Eli Lilly are printing money at a scale that is genuinely without precedent in the pharmaceutical industry's history.